Medicines for human use under evaluation 2017–2015

Monthly lists of medicines for human use under evaluation by the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) from 2017–2015 are available on this page.

The CHMP meets once per month. All monthly lists of medicines that were under evaluation by the CHMP can be found in this section, dating back to 2012.

Monthly lists 2017

Applications for new human medicines under evaluation by the CHMP: December 2017

Reference Number: EMA/789956/2017

Applications for new human medicines under evaluation by the CHMP: November 2017

Reference Number: EMA/716196/2017 Summary:

This document lists information on applications for centralised marketing authorisation for human medicines that the European Medicines Agency has received for evaluation.

Applications for new human medicines under evaluation by the CHMP: October 2017

Reference Number: EMA/661972/2017

Applications for new human medicines under evaluation by the CHMP: September 2017

Reference Number: EMA/583158/2017

Applications for new human medicines under evaluation by the CHMP: August 2017

Reference Number: EMA/506776/2017

Applications for new human medicines under evaluation by the CHMP: July 2017

Reference Number: EMA/430827/2017 Summary:

This document lists information on applications for centralised marketing authorisation for human

medicines that the European Medicines Agency has received for evaluation. It includes the international

non-proprietary names (INN) and therapeutic areas for all new innovative medicines under evaluation

by the Committee for Medicinal Products for Human Use (CHMP).

Applications for new human medicines under evaluation by the CHMP: June 2017

Reference Number: EMA/352726/2017

Applications for new human medicines under evaluation by the CHMP: May 2017

Reference Number: EMA/283079/2017

Applications for new human medicines under evaluation by the CHMP: April 2017

Reference Number: EMA/225209/2017

Applications for new human medicines under evaluation by the CHMP: March 2017

Reference Number: EMA/169426/2017

Applications for new human medicines under evaluation by the CHMP: February 2017

Reference Number: WC500221554

Applications for new human medicines under evaluation by the CHMP: January 2017

Reference Number: EMA/4827/2017

Monthly lists 2016

Applications for new human medicines under evaluation by the CHMP: December 2016

Reference Number: EMA/810788/2016

Applications for new human medicines under evaluation by the CHMP: November 2016

Reference Number: EMA/735168/2016

Applications for new human medicines under evaluation by the CHMP: October 2016

Reference Number: EMA/655666/2016 Summary:

This document lists information on applications for centralised marketing authorisation for human

medicines that the European Medicines Agency has received for evaluation.

Applications for new human medicines under evaluation by the CHMP: September 2016

Reference Number: EMA/607298/2016

Applications for new human medicines under evaluation by the CHMP: August 2016

Reference Number: EMA/529158/2016 Summary:

This document lists information on applications for centralised marketing authorisation for human

medicines that the European Medicines Agency has received for evaluation. It includes the international

non-proprietary names (INN) and therapeutic areas for all new innovative medicines under evaluation

by the Committee for Medicinal Products for Human Use (CHMP).

Applications for new human medicines under evaluation by the CHMP: July 2016

Reference Number: EMA/462942/2016

Applications for new human medicines under evaluation by the CHMP: June 2016

Reference Number: EMA/403916/2016 Corr

Applications for new human medicines under evaluation by the CHMP: May 2016

Reference Number: EMA/325064/2016

Applications for new human medicines under evaluation by the CHMP: April 2016

Reference Number: EMA/269096/2016 Summary:

This document lists information on applications for centralised marketing authorisation for human

medicines that the European Medicines Agency has received for evaluation. It includes the international

non-proprietary names (INN) and therapeutic areas for all new innovative medicines under evaluation

by the Committee for Medicinal Products for Human Use (CHMP).

Applications for new human medicines under evaluation by the CHMP: March 2016

Reference Number: EMA/182466/2016 Summary:

This document lists information on applications for centralised marketing authorisation for human medicines that the European Medicines Agency has received for evaluation.

Applications for new human medicines under evaluation by the CHMP: February 2016

Reference Number: EMA/93292/2016

Applications for new human medicines under evaluation by the CHMP: January 2016

Reference Number: EMA/6499/2016 Summary:

This document lists information on applications for centralised marketing authorisation for human medicines that the European Medicines Agency has received for evaluation. It includes the international non-proprietary names (INN) and therapeutic areas for all new innovative medicines under evaluation by the Committee for Medicinal Products for Human Use (CHMP).

Monthly lists 2015

Applications for new human medicines under evaluation by the CHMP: December 2015

Reference Number: EMA/825991/2015 Summary:

This document lists information on applications for centralised marketing authorisation for human

medicines that the European Medicines Agency has received for evaluation. It includes the international

non-proprietary names (INN) and therapeutic areas for all new innovative medicines under evaluation

by the Committee for Medicinal Products for Human Use (CHMP).

Applications for new human medicines under evaluation by the CHMP: November 2015

Reference Number: EMA/731936/2015

Applications for new human medicines under evaluation by the CHMP: October 2015

Reference Number: EMA/657412/2015

Applications for new human medicines under evaluation by the CHMP: September 2015

Reference Number: EMA/599965/2015 Summary:

This document lists information on applications for centralised marketing authorisation for human

medicines that the European Medicines Agency has received for evaluation. It includes the international non-proprietary names (INN) and therapeutic areas for all new innovative medicines under evaluation by the Committee for Medicinal Products for Human Use (CHMP).

Applications for new human medicines under evaluation by the CHMP: August 2015

Reference Number: EMA/541870/2015

Applications for new human medicines under evaluation by the CHMP: July 2015

Reference Number: EMA/463668/2015

Applications for new human medicines under evaluation by the CHMP: June 2015

Reference Number: EMA/383502/2015 Summary:

This document lists information on applications for centralised marketing authorisation for human medicines that the European Medicines Agency has received for evaluation.

Applications for new human medicines under evaluation by the CHMP: May 2015

Reference Number: EMA/315740/2015

Applications for new human medicines under evaluation by the CHMP: April 2015

Reference Number: EMA/227980/2015 Corr.

Applications for new human medicines under evaluation by the CHMP: March 2015

Reference Number: EMA/158334/2015

Applications for new human medicines under evaluation by the CHMP: February 2015

Reference Number: EMA/82478/2015 Summary:

This document lists information on applications for centralised marketing authorisation for human medicines that the European Medicines Agency has received for evaluation. It includes the international

non-proprietary names (INN) and therapeutic areas for all new innovative medicines under evaluation

by the Committee for Medicinal Products for Human Use (CHMP). For generic and biosimilar medicines,

it includes the INN (active moiety only, with no information on salt, ester or derivative) and therapeutic area.

Applications for new human medicines under evaluation by the CHMP: January 2015

Reference Number: EMA/9499/2015 Summary:

This document lists information on applications for centralised marketing authorisation for human medicines that the European Medicines Agency has received for evaluation. It includes the international non-proprietary names (INN) and therapeutic areas for all new innovative medicines under evaluation

by the Committee for Medicinal Products for Human Use (CHMP). For generic and biosimilar medicines,

it includes the INN (active moiety only, with no information on salt, ester or derivative) and therapeutic area.

More lists:

• Medicines for human use under evaluation 2014–2012